


RHÖN-KLINIKUM AG



Invitation to the
Annual General Meeting
on 9 June 2010

RHÖN-KLINIKUM AG
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale
Germany

ISIN No. DE0007042301
German Securities Code 704230

We hereby invite our shareholders to attend the

**Annual General Meeting
of RHÖN-KLINIKUM Aktiengesellschaft**

which will be held on

Wednesday, 9 June 2010, 10.00 a.m.,

at the Jahrhunderthalle Frankfurt,
Pfaffenwiese, 65929 Frankfurt am Main,
Germany.

AGENDA

1. Presentation of the approved Annual Financial Statements and the Consolidated Financial Statements for the year ended 31 December 2009, as well as the Management Reports on the situation of the Company and of the Group for the financial year 2009 (including the notes on the disclosures pursuant to Sections 289 (4) and (5), 315 (4) of the German Commercial Code (*Handelsgesetzbuch, HGB*), respectively, for the financial year 2009) and the Report of the Supervisory Board for the financial year 2009.

The shareholders may inspect the aforementioned documents as well as the dividend proposal of the Management Board from the date of convening the Annual General Meeting on the Company's premises in D-97616 Bad Neustadt a. d. Saale, Salzburger Leite 1. On request, every shareholder will be provided with a copy of these docu-

ments without delay and free of charge. The documents will also be displayed for inspection at the Annual General Meeting and are made available on the internet homepage of the Company at <http://www.rhoen-klinikum-ag.com/agm> from the date of convening of the Annual General Meeting.

The above documents shall be made available at the Annual General Meeting. They will be explained by the Management Board and – as regards the Report of the Supervisory Board – by the chairman of the Supervisory Board in the course of the Annual General Meeting. In accordance with the relevant statutory provisions, no resolution on this Agenda Item will be passed. The Supervisory Board has approved the Annual Financial Statements prepared by the Management Board and the Consolidated Financial Statements on 27 April 2010. The Annual Financial Statements are thus adopted.

2. Resolution on the appropriation of the net distributable profit

The Annual Financial Statements of RHÖN-KLINIKUM Aktiengesellschaft for the year ended 31 December 2009 as prepared by the Management Board, as approved by the Supervisory Board and thus adopted as a consequence, disclose a net distributable profit in the amount of € 41,469,600.00. The Management Board and the Supervisory Board propose

that a portion of the net distributable profit in the amount of € 41,462,400.00

be appropriated for distribution of a dividend of € 0.30 per no-par value share with dividend entitlement (DE0007042301)

and to carry forward to new account the remaining amount of € 7,200.00.

3. Resolution on formal approval of the actions of the members of the Management Board for the financial year 2009

For the financial year 2009, the Management Board and the Supervisory Board propose that formal approval be granted to the members of the Management Board in office in financial year 2009 for their actions.

4. Resolution on formal approval of the actions of the members of the Supervisory Board for the financial year 2009

For the financial year 2009, the Management Board and the Supervisory Board propose that formal approval be granted to the members of the Supervisory Board officiating in financial year 2009 for their actions.

5. Resolution on the approval of the remuneration system for the members of the Management Board

The German Act on the Appropriateness of Executive Remuneration (*Gesetz zur Angemessenheit der Vorstandsvergütung*, VorstAG) has made it possible for the Annual General Meeting to resolve on the approval of the remuneration system for the members of the Management Board (Section 120 (4) of the German Stock Corporation Act (*Aktienengesetz*, "AktG")). The remuneration system for the members of the Management Board of the Company is described in detail in the Remuneration Report which has been published in the Annual Report 2009 as a part of the Corporate Governance Report.

The Management Board and the Supervisory Board propose that the remuneration system be approved.

6. Election of the statutory auditor for the financial year 2010

The Supervisory Board proposes that the Annual General Meeting 2010 elects **PricewaterhouseCoopers Aktiengesellschaft Wirtschaftsprüfungsgesellschaft**, Frankfurt am Main, as auditors for the Annual Financial Statements of the AG and the Consolidated Financial Statements for the financial year 2010 as well as for a review of the interim financial statements for the first half year 2010.

7. Resolution on a new authorisation to purchase and use treasury shares pursuant to Section 71 (1) No. 8 AktG as well as on the exclusion of subscription rights

The Company may only purchase treasury shares based on an authorisation by the Annual General Meeting, except where such purchase is expressly permitted by law. Since the authorisation granted by virtue of the resolution of the Annual General Meeting on 10 June 2009 expires on 9 December 2010, the Annual General Meeting will be asked to resolve a new authorisation to purchase treasury shares. Pursuant to Section 71 (1) No. 8 AktG, as amended by the German Act Implementing the Shareholder Rights Directive (*Gesetz zur Umsetzung der Aktionärsrechterichtlinie*, ARUG), an authorisation may now be granted for a period of up to five years. It is proposed to make use of this option. This new option, however, does not include a change in the scope of the authorisation.

The Management Board and the Supervisory Board therefore propose to resolve as follows:

- a) The authorisation to purchase treasury shares granted by resolution of

the Annual General Meeting on 10 June 2009 is revoked upon the following authorisation taking effect.

b) The Management Board is authorised, subject to the consent of the Supervisory Board, to purchase treasury shares up to a total amount equal to no more than 10% of the present registered share capital until 8 June 2015. Repurchases may be effected on the stock market or by way of a purchase offer to all shareholders.

(1) If repurchases are effected on the stock market, the purchase price per share paid by the Company (excluding ancillary purchasing costs) may not be more than 10 per cent higher or lower than the share price of RHÖN-KLINIKUM shares as determined in the opening auction on the respective trading day in Xetra trading (or on any comparable trading system substituting Xetra) on the Frankfurt Stock Exchange.

(2) If repurchases are effected by way of a public purchase offer, the price per share offered by the Company for the repurchase of the shares (excluding ancillary purchasing costs) may not be more than 20 per cent higher or lower than the mean value of the closing prices of RHÖN-KLINIKUM shares as determined in Xetra trading (or on any comparable trading system substituting Xetra) on the Frankfurt Stock Exchange for the five trading days immediately preceding the date on which the offer is published. Where, following a public purchase offer, the number of shares tendered to the Company exceeds the planned volume of repurchase, the purchase of the shares by the Company shall take place at the ratio of the

shares offered. Preferential acceptance of offers may be given for small numbers of up to 50 tendered shares per shareholder.

(3) This authorisation may be used by the Company or entities controlled by the Company within the meaning of Section 17 AktG or by third parties for the account of the Company or such controlled entities on one or several occasions, to the full extent of repurchases thereby authorised or to a lesser extent. The aggregate of treasury shares already purchased and held by the Company, or attributable to it in accordance with Sections 71 a et seq. AktG, and treasury shares repurchased by virtue of this authorisation shall not exceed 10 per cent of the Company's registered share capital at any one time.

c) The Management Board is hereby authorised, subject to the consent of the Supervisory Board, to make use of all or part of the shares repurchased on the basis of this or any previously granted authorisation, also by means other than by disposal via the stock market or through an offer to all shareholders and thereby excluding the pre-emption rights of the shareholders, insofar as the treasury shares

(1) are issued against contribution in kind, in particular in connection with the acquisition of companies, interests in companies, parts of companies or business combinations;

(2) are sold to third parties against cash consideration, provided that, in line with Section 186 (3) sentence 4 AktG, the purchase price is not substantially lower than the market price of the RHÖN-KLINIKUM shares at the

date of sale. However, this shall apply only on the condition that the number of repurchased shares to be sold together with the number of new shares issued since the granting of the present authorisation ex subscription rights pursuant to Section 186 (3) sentence 4 AktG shall not in the aggregate exceed 10 per cent of the registered share capital on neither the effective date nor the exercise date of the present authorisation.

Lastly, subject to approval by the Supervisory Board, the Management Board is authorised to redeem part or all of the treasury shares repurchased by virtue of this or any previously granted authorisation without any further shareholders' resolution.

Report of the Management Board to the Annual General Meeting pursuant to Section 71 (1) No. 8 AktG in conjunction with Section 186 (4) sentence 2 AktG with regard to Agenda Item 7

The Management Board submitted a written report on Agenda Item 7 pursuant to Sections 71 (1) No. 8, 186 (4) sentence 2 AktG. From the date of the convening of the Annual General Meeting, the report is available on the premises of the Company for inspection by the shareholders. On request, a copy of this report will be sent to every shareholder without delay and free of charge. The report will also be displayed for inspection at the Annual General Meeting and is made available on the internet homepage of the Company at <http://www.rhoen-klinikum-ag.com/agm> from the date of convening of the Annual General Meeting.

The report is published with the following content:

Agenda Item 7 contains the proposal to authorise the Company to purchase treasury shares up to an amount equal to no more than 10 per cent of the current registered share capital in the period from the date of adoption of the resolution until 8 June 2015.

The Annual General Meeting of 10 June 2009 had already authorised the Company for a period of 18 months, i.e. until 9 December 2010, to purchase treasury shares in an amount of up to 10 per cent of the registered share capital and, subject to certain conditions, to dispose of these shares by means other than via the stock market or through an offer to all shareholders. This authorisation has not been exercised to date. Since the authorisation expires before the 2011 Annual General Meeting, a new authorisation is required in order to be able to purchase treasury shares also in the future.

Pursuant to Section 71 (1) No. 8 AktG, as amended by the German Act Implementing the Shareholder Rights Directive (ARUG), an authorisation may now be granted for a period of up to five years. It is proposed to make use of this option. This new option, however, does not include a change in the scope of the authorisation. If the volume covered by the authorisation is used up prior to the expiry of the five years' period, the Company may submit to the Annual General Meeting a new resolution proposal regarding the authorisation to repurchase treasury shares.

When purchasing treasury shares, the principle of equal treatment of shareholders pursuant to Section 53a AktG must be observed. The proposed purchase of treasury shares via the stock market or by way of public purchase offer gives due regard to this principle. In the event that, following a public purchase offer, the number of shares tendered for repurchase at the price determined exceeds the volume of the pur

chase offer, it will be necessary to allocate quotas. In this context it will be possible to provide for a preferential acceptance of small tenders or small parts of tenders up to a maximum of 50 shares, the purpose of which is to avoid fractional amounts in the determination of the quotas to be purchased as well as small residual amounts in order to facilitate technical execution.

In accordance with the proposed authorisation, the treasury shares purchased by the Company may be either redeemed or resold by way of an offer to all shareholders or via the stock market. The latter two possibilities of disposing of purchased treasury shares respect the shareholders' right to equal treatment also in the event the shares are sold.

The authorisation further provides, in line with the statutory provision in Section 71 (1) No. 8 sentence 5 AktG, that the Company, subject to the consent of the Supervisory Board, may dispose of purchased treasury shares other than via the stock market or other than by way of an offer to all shareholders, thereby excluding the shareholders' pre-emption right, if such treasury shares, pursuant to Section 186 (3) sentence 4 AktG, are sold at a price which is not substantially lower than the stock market price of the share of RHÖN-KLINIKUM AG at the time of the sale, and provided that the number of the repurchased shares to be sold together with the new shares issued ex subscription rights since the granting of the present authorisation pursuant to Section 186 (3) sentence 4 AktG shall not in the aggregate exceed 10 per cent of the registered share capital of the Company on neither the effective date nor the exercise date of the present authorisation. The possibility of disposal other than via the stock market or by way of an offer to all shareholders is in the interest of the Company and of the shareholders as the disposal of shares, for example to institutional investors, allows the Com-

pany to attract and gain additional domestic and international shareholders. This authorisation will enable the Company to respond quickly and flexibly to the given stock market situation.

By limiting the sale of treasury shares to a maximum amount of 10 per cent of the registered share capital, it is ensured that both the economic as well as the voting interests of the shareholders are not unduly impaired also in the event of a sale of the treasury shares ex pre-emption rights of the shareholders. Since the shares sold ex pre-emption rights of the shareholders may only be sold at a price which is not substantially lower than the stock market price of the share of RHÖN-KLINIKUM AG at the time of the sale, shareholders do not incur any disadvantage since they may acquire the requisite number of shares to preserve their participation ratio on nearly identical terms via the stock market. The Management Board shall – giving due regard to the respective stock market situation – endeavour to keep any discount on the stock market price permitted within the scope of Section 186 (3) sentence 4 AktG as low as possible.

Furthermore, the Company is to be given the possibility of using treasury shares as (partial) consideration for the acquisition of other companies, interests in companies or of parts of companies as well as for business combinations. For this reason, the authorisation provides for the possibility, subject to the consent of the Supervisory Board, to dispose of all or part of the purchased treasury shares by means other than via the stock market or through an offer to all shareholders, thereby excluding the subscription right, provided that this is made against contribution in kind in connection with the aforementioned purpose.

The Company is also to be enabled to expand in future through further take-overs of hospitals. The legal provisions

of German hospital requirement planning in the area of acute inpatient healthcare delivery to statutorily insured patients do not legally rule out growth through the establishment of new hospitals, but this is virtually impossible in practice. Further expansion will be achieved first and foremost through the acquisition of existing hospitals. The proposed authorisation gives the Management Board the requisite manoeuvring room to quickly and flexibly respond, in the interests of the Company and its shareholders, to favourable offers or to other opportunities as they arise and to exploit the scope for expansion by acquiring companies or interests in companies, also using treasury shares as an acquisition currency.

After weighing up all these circumstances, the authorisations set forth in the resolution proposal for the exclusion of pre-emption rights in the event of a disposal at a price close to the stock market price and for the acquisition of companies and interests in companies are necessary, suitable, reasonable and expedient in the interests of the Company.

There are currently no specific plans to exercise such authorisation. The Management Board, however, will report to the Annual General Meeting in each case that the authorisation is exercised.

8. Elections to the Supervisory Board

Pursuant to Section 10 para. 1 of the Articles of Association, Sections 96 (1) and 101 (1) AktG and Section 7 (1) sentence 1 no. 3 of the German Co-Determination Act, (*Mitbestimmungsgesetz*, MitBestG) dated 4 May 1976, the Company's Supervisory Board is composed of 20 members, ten of whom are elected by the Annual General Meeting and ten by the employees.

At the end of the Annual General Meeting on 9 June 2010, both the term of the ten Supervisory Board members elected

by the Annual General Meeting as well as the term of the ten members elected by the employees, shall end. The election of the employee representatives will presumably be completed on 20 May 2010. The ten Supervisory Board members chosen by the Annual General Meeting are therefore to be elected by the Annual General Meeting. The Annual General Meeting is not bound to candidate proposals in this regard.

In accordance with the recommendations of the German Corporate Governance Code, it is intended to proceed with the elections by way of individual nominations (*Einzelwahl*).

The Supervisory Board proposes to elect the following persons as shareholder representatives to the Supervisory Board:

8.1 Eugen Münch, Bad Neustadt a. d. Saale, Chairman of the Supervisory Board

It is intended that Mr Münch will again run for the position of Chairman on the Supervisory Board. Mr Münch is a member of the following statutorily prescribed Supervisory Boards and similar domestic or foreign supervisory bodies of commercial businesses:

- Advisory Council of the Deutsche Hospizstiftung
- Advisory Council of the Deutsche Schlaganfall-Hilfe
- Member of the Presidential Committee of the Würzburg/Schweinfurt chamber of trade and commerce (*Industrie- und Handelskammer, IHK*)
- Deputy Chairman of the Management Board of the Bundesverband Deutscher Privatkliniken e.V.

8.2 Prof Dr Gerhard Ehninger, Dresden, medical doctor and director of the university hospital in Dresden

Prof Dr Ehninger is a member of the following statutorily prescribed Su-

Supervisory Boards and similar domestic or foreign supervisory bodies of commercial businesses:

- Supervisory Board of the Universitätsklinikum Gießen und Marburg GmbH, Gießen
- Advisory Council of the DKMS Stiftung Leben spenden, Tübingen
- Board Member of DKMS America, New York, USA
- Board Member of DKMS Polska, Warsaw, Poland.

8.3 Caspar von Hauenschild, Munich, self-employed management consultant

Mr von Hauenschild is a member of the following statutorily prescribed Supervisory Boards and similar domestic or foreign supervisory bodies of commercial businesses:

- Supervisory Board of St. Gobain ISOVER AG, Ludwigshafen
- Advisory Board of oekomresearch AG, Munich.

8.4 Detlef Klimpe, Aachen, German lawyer (Rechtsanwalt) in the law practice Leinen & Derichs, Cologne

Mr Klimpe is a member of the following statutorily prescribed Supervisory Boards and similar domestic or foreign supervisory bodies of commercial businesses:

- Supervisory Board of the Universitätsklinikum Gießen und Marburg GmbH, Gießen

8.5 Prof Dr Dr sc (Harvard) Karl W. Lauterbach, Cologne, member of the German Parliament (*Bundestag*)

Prof Dr Dr sc (Harvard) Lauterbach is not a member of statutorily prescribed Supervisory Boards or similar domestic or foreign supervisory bodies of commercial businesses.

8.6 Michael Mendel, Vienna, Austria, member of the Management Board of the Austrian Volksbanken-AG

Mr Mendel is a member of the following statutorily prescribed Supervisory Boards and similar domestic or foreign supervisory bodies of commercial businesses:

- Supervisory Board of Altium AG, Munich
- Supervisory Board of Aveco AG, Frankfurt am Main

8.7 Dr Brigitte Mohn, Gütersloh, member of the Management Board of the Bertelsmann Foundation

Dr Mohn is a member of the following statutorily prescribed Supervisory Boards and similar domestic or foreign supervisory bodies of commercial businesses:

- Chairman of the Supervisory Board of Phineo gAG, Berlin
- Supervisory Board of Bertelsmann AG, Gütersloh
- Advisory Board of MEDICLIN AG, Offenburg
- Advisory Board of the Help-Group, Bonn-Alfter
- Chairman of the Management Board of the Stiftung Deutsche Schlaganfall-Hilfe, Gütersloh
- Member of the Board of Trustees of the Deutsche Kinderturnstiftung, Frankfurt am Main
- Member of Bertelsmann Verwaltungsgesellschaft mbH
- Member of the Board of Trustees of the Stiftung Michael Skopp, Bielefeld
- Deputy Chairman of the Management Board of the Stiftung Praxissiegel e.V., Gütersloh
- Member of the Board of Trustees of the Stiftung Dialog der Generationen, Düsseldorf
- Member of the Advisory Council of the Stiftung Wittenberg-Zentrum für globale Ethik, Lutherstadt Wittenberg.

- 8.8 Wolfgang Mündel, Kehl, self-employed accountant and tax advisor

Mr Mündel is a member of the following statutorily prescribed Supervisory Boards and similar domestic or foreign supervisory bodies of commercial businesses:

- Chairman of the Advisory Board of Jean d'Arcel Cosmétique GmbH & Co KG, Kehl.

- 8.9 Jens-Peter Neumann, Paphos, Cyprus, self-employed management consultant

Mr Neumann is not a member of statutorily prescribed Supervisory Boards or similar domestic or foreign supervisory bodies of commercial businesses.

- 8.10 Dr Rüdiger Merz, Munich, Managing Director of Clemens Haindl Verwaltungs GmbH

Dr Merz is not a member of statutorily prescribed Supervisory Boards and similar domestic or foreign supervisory bodies of commercial businesses.

The election is made for the period until the end of the Annual General Meeting which formally approves the actions of the Supervisory Board for the 2014 financial year. The term of each member of the Supervisory Board shall in any case expire at the end of that Annual General Meeting, before the beginning of which such Supervisory Board member reaches 70 years of age.

9. Resolution on the amendment of the Articles of Association to comply with the German Act Implementing the Shareholder Rights Directive (ARUG)

The German Act Implementing the Shareholder Rights Directive has

changed the corporate law deadlines for registration for the Annual General Meeting and for proof of the entitlement to participate.

The Management Board and the Supervisory Board therefore propose to fully restate Section 16 of the Articles of Association (Conditions for participation):

„§ 16

Conditions for participation

1. Shareholders who wish to participate in the Annual General Meeting or exercise their voting rights shall register for the Annual General Meeting and provide proof of their entitlement to participate. The registration and the evidence of entitlement must be received by the Company, at the address indicated for this purpose in the convening notice, at least six days before the Annual General Meeting (registration deadline). The day of the Annual General Meeting and the day of the receipt of the registration shall not be counted.
2. Special proof of shareholding, issued in text form by the custodian institution, shall suffice as proof of entitlement as per para. 1. Proof of shareholding regarding shares not held in a securities account at a credit institution or in collective custody (*Girosammelverwahrung*) may also be issued by a German notary, the Company or a credit institution, against presentation of the shares. The proof of shareholding must apply to the point in time set out for this purpose in the German Stock Corporation Act.

The Company shall be entitled, in cases of doubt about the correctness or authenticity of the proof of entitlement, to request suitable further proof. Should there also be doubts about the latter, the Company may refuse the shareholder's entitlement to participate in the An-

nual General Meeting or exercise his or her voting rights.

3. The registration and the proof of shareholding shall be in German or English, other languages may be authorised in the convening notice."

FURTHER INFORMATION ON THE CONVENING OF THE ANNUAL GENERAL MEETING AND ON THE ANNUAL GENERAL MEETING

We have asked the credit institutions to forward the convening notice for the Annual General Meeting to all shareholders for whom they hold the shares in RHÖN-KLINIKUM AG in custody. Shareholders who do not receive this information by two weeks before the Annual General Meeting are requested to order these documents from their respective custodian bank.

1. Prerequisites for the participation in the Annual General Meeting and the exercise of voting rights

Those shareholders shall be entitled to participate in the Annual General Meeting and to exercise their voting rights who register with the Company under the following address and submit special proof of their shareholding issued by their custodian institution to the following address:

RHÖN-KLINIKUM AG
c/o Computershare
HV-Services AG
Prannerstraße 8
80333 Munich,
Germany; or

by fax: +49 (0)89 / 3090374675; or

by email:
anmeldestelle@computershare.de

The proof of shareholding must refer to the commencement of the 21st day before the Annual General Meeting, that is 19 May 2010, 00.00 hrs, ("Record Date") and be received by the Com-

pany together with the registration no later than 2 June 2010 (24.00 hrs) at the address specified. Under the specified contact data, Computershare HV-Services AG will act as the Company's agent for receipt. The proof of shareholding with respect to shares not held in a securities account of a credit institution or in collective custody may also be issued by a German notary, the Company or a credit institution against presentation of the shares. The registration and the proof of shareholding must be in text form (Section 126 b German Civil Code (*Bürgerliches Gesetzbuch*, BGB) and in the German or English language.

After receipt of the registration and the proof of shareholding by the Company, the shareholders will be sent an admission ticket for the Annual General Meeting bearing their name, stating the number of shares for which proof has been furnished and at the same time serving as a ticket of admission to the Annual General Meeting for a representative presenting proper proof of identification. To ensure that they receive the admission tickets on time, we kindly ask the shareholders to make early arrangement for their registration and proof to be submitted.

As regards the participation in the meeting or the exercise of voting rights, only such person is deemed to be a shareholder in relation to the Company who has furnished special proof of shareholding. The entitlement to participate or the scope of the voting right is exclusively based on the shareholding as at the Record Date. The Record Date does not entail a lock-up on the disposal of shares. Even in the event of a complete or partial disposal of the shareholding after the Record Date, only the shareholding of the registered person as at the Record Date will be relevant for the participation and the scope of the voting right; this means that sales of shares after the Record Date do not have any effect on the entitlement to participate in the Annual General Meeting and the scope of voting rights. The same shall apply if

shares are newly or additionally acquired after the Record Date. Persons who do not hold any shares at the Record Date and become shareholders only after that date will only be entitled to participate in the meeting and the voting with respect to the shares held by them insofar as they are appointed as proxy or are granted authorisation to participate and exercise these rights.

2. Representation for voting by proxy

Shareholders not wishing to participate in the Annual General Meeting in person may exercise their voting rights by appointing a proxy, e.g. a credit institution, a shareholders' association, third parties or proxies appointed by the Company. Also in this case, a timely registration together with the submission of the proof of shareholding will be required.

The shareholders who have registered for the Annual General Meeting in due time receive a proxy form together with the admission ticket form. Furthermore, a form for granting of proxy voting rights as well as a form for revoking such grant will be available on the internet homepage of the Company at <http://www.rhoen-klinikum-ag.com/agm> shortly after convening of the Annual General Meeting. Shareholders wishing to appoint a proxy are requested to preferentially use the proxy form sent along with the admission ticket in order to issue such authorisation.

Generally, the grant of authorisation, the revocation and proof of such authorisation to the Company need to be in text form if the proxy for the exercise of voting rights is neither a credit institution nor a shareholders' association nor any other institution or legal entity which is equated to them pursuant to Sections 135 (8) and (10) AktG.

If an authorisation to exercise voting rights is granted to credit institutions, institutions or corporations equated to them (Sections 135 (10), 125 (5) AktG) and to shareholders' associations or le-

gal entities within the meaning of Section 135 (8) AktG, some specific features usually have to be taken into account: text form is not required, but the proxy must record the authorisation in a verifiable form; in addition, it has to be complete and may only include statements related to the exercise of voting rights. We therefore request our shareholders to consult on this issue with the credit institutions, shareholders' associations or legal entities or institutions equated to such credit institutions and shareholders' associations.

If a shareholder appoints more than one person as proxy, the Company may reject one or several of them.

Any authorisation must either be evidenced by the proxy at the date of the Annual General Meeting; it is also possible to issue an authorisation and provide the respective evidence by way of a declaration vis-à-vis the Company, which may be sent by post or electronically by e-mail and must be received at the following address no later than 8 June 2010, 24.00 hrs:

RHÖN-KLINIKUM AG
- Hauptversammlung -
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale,
Germany; or

by email: hv@rhoen-klinikum-ag.com

We offer our shareholders the possibility of authorising proxies, who are appointed by the Company and bound by instructions, prior to the Annual General Meeting. A form for granting of proxy voting rights and issuing of instructions for representation by proxies appointed by the Company will be provided to the shareholders on the admission ticket form for the Annual General Meeting. The form for granting of authorisation to the proxies appointed by the Company will also be available on the internet homepage of the Company at <http://www.rhoen-klinikum-ag.com/agm> shortly after convening of the Annual General Meeting. However, there is no obligation to use the form offered by the

Company in order to authorise, or issue instructions to, proxies appointed by the Company. All proxies appointed by the Company, however, require in each case clear voting instructions by shareholders regarding the individual items of the Agenda which are subject to resolution. Otherwise, their authorisation will be null and void. The proxies are obliged to vote in accordance with the instructions given by the shareholders.

Shareholders wishing to take advantage of the opportunity to authorise a proxy or proxies appointed by the Company are kindly asked to order their admission ticket as soon as possible to ensure that their admission ticket is available in due time.

The authorisation of proxies appointed by the Company, the revocation and the proof of such authorisation vis-à-vis the Company need to be in text form, as well. However, we kindly ask you to also sign the authorisation of proxies appointed by the Company before you submit it to us; this is to ensure that we can record the authorisation in a verifiable form. Further details regarding the authorisation of and voting instructions to proxies appointed by the Company prior to the Annual General Meeting are given on the admission ticket form. The authorisation of and voting instructions to proxies appointed by the Company must be received by the Company by post or electronically by e-mail at the following address no later than 8 June 2010, 24.00 hrs:

RHÖN-KLINIKUM AG
- Hauptversammlung -
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale,
Germany; or

by email: hv@rhoen-klinikum-ag.com

3. Shareholder motions and voting proposals, right to obtain information

a) Supplemental Items upon request of a minority (Section 122 (2) AktG)

Shareholders whose shares together reach the pro-rata portion of the registered share capital of € 500,000 (this corresponds to 200,000 shares) may request that items be put on the Agenda and be announced. Each new Agenda Item has to be submitted with a statement of reasons or a resolution proposal. The request is to be addressed to the Management Board in writing and must be received by the Company at the below address at least 30 days prior to the meeting, i.e. no later than 9 May 2010, 24.00 hrs:

RHÖN-KLINIKUM AG
- Management Board -
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale,
Germany

b) Shareholder motions and voting proposals (Sections 126 (1) and 127 AktG)

Pursuant to Section 126 (1) AktG, each shareholder is entitled to submit counterproposals to the resolutions proposed by the Management Board and the Supervisory Board regarding Agenda Items. The same applies to counterproposals to voting proposals regarding the election of members of the Supervisory Board and auditors (Section 127 AktG). Such counterproposals are to be directed exclusively to:

RHÖN-KLINIKUM AG
- Hauptversammlung -
Salzburger Leite 1
97616 Bad Neustadt a.d. Saale,
Germany; or

by email: hv@rhoen-klinikum-ag.com

The Company – subject to Sections 126 (2) and (3), 127 AktG – will immediately make all counterproposals and voting proposals by other shareholders which are submitted to this address at least 14 days prior to the Annual General Meeting, i.e. no later than 25 May 2010, 24.00 hrs available to all shareholders on the internet homepage of the Company at <http://www.rhoen-klinikum-ag.com/agm>. Any statements by the management will also be pub-

lished at the above internet address subsequently.

c) Shareholder's right to obtain information (Section 131 (1) AktG)

Upon request, each shareholder is entitled to obtain information from the Management Board regarding the matters of the Company in the Annual General Meeting, including the legal and business relations with affiliated companies as well as information on the situation of the Group and the companies integrated in the Consolidated Financial Statements, provided that such information is required for an appropriate evaluation of the relevant Agenda Item.

d) Further explanations on shareholder rights

Further explanations on the shareholders' rights pursuant to Sections 122 (1), 126 (1), 127, 131 (1) AktG are available on the internet homepage of the Company at <http://www.rhoen-klinikum-ag.com/agm> from the date of convening of the Annual General Meeting.

4. Total number of shares and voting rights

At the date of convening of the Annual General Meeting, RHÖN-KLINIKUM AG has issued 138,232,000 no-par value bearer shares in the aggregate which as a rule confer the same number of votes. However, upon convening of this Annual General Meeting, the Company holds 24,000 treasury shares. The Company is not entitled to voting rights from these shares. The total number of participating and voting shares thus amounts to 138,208,000 at the time of

convening of this Annual General Meeting.

5. Documents in connection with the Annual General Meeting and further information

This invitation to the Annual General Meeting, all documents to be made available at the Annual General Meeting, in particular the documents regarding Agenda Item 1 and Agenda Item 7 as well as any further information in connection with the Annual General Meeting, particularly pursuant to Section 124a AktG, are available for inspection on the internet homepage of the Company at

<http://www.rhoen-klinikum-ag.com/agm>

from the date of convening of the Annual General Meeting.

The documents to be made available will also be displayed for inspection at the Annual General Meeting on 9 June 2010. Any counterproposals, voting proposals and supplemental requests of shareholders which are received by the Company and are subject to publication will also be made available on the aforementioned internet homepage.

The invitation to the Annual General Meeting with Agenda is published in the electronic Federal Gazette (*elektronischer Bundesanzeiger*) on 30 April 2010.

Bad Neustadt a. d. Saale, 30 April 2010

RHÖN-KLINIKUM AG
The Management Board